Ozone Therapy as a Controlled Modulator of Redox Signaling and Adaptive Stress Responses: Molecular Mechanisms, Hormetic Effects, and Biomedical Implications
Abstract
1. Introduction
2. Chemical Reactivity of Ozone in Biological Systems
3. Redox Compartmentalization and Temporal Dynamics of Ozone Signaling
4. Redox Signaling and Antioxidant Network Reprogramming
5. Redox Control of Inflammatory and Inflammasome Signaling
6. Tissue-Level Integration of Redox Signaling in the Skin and Subcutaneous Tissue
6.1. Fibroblast Redox Regulation and Matrix Dynamics
6.2. Adipose Tissue as an Immunometabolic Redox Organ
6.3. Melanocyte Redox Homeostasis and Pigmentation Networks
6.4. Integrated Redox Adaptation in Tissue Aging and Remodeling
7. Translational Integration: From Redox Mechanisms to Clinical Hypotheses
7.1. Inflammatory Skin Disorders
7.2. Adipose Tissue Remodeling
7.3. Tissue Repair and Structural Aging
7.4. Pigmentation Dynamics
7.5. Translational Boundaries and Evidence Gaps
8. Dose-Dependent Redox Dynamics and Safety Constraints
8.1. Hormetic Windows and Threshold Behavior
8.2. Safety Constraints and Redox Buffering Capacity
8.3. Methodological Heterogeneity and Evidence Quality
8.4. Regulatory Variability and Conceptual Framing
8.5. Critical Perspective and Future Directions
9. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
| 4-HNE | 4-Hydroxynonenal |
| IL-1β | Interleukin-1 beta |
| IL-6 | Interleukin-6 |
| Keap1 | Kelch-like ECH-associated protein 1 |
| MAPK | Mitogen-activated protein kinase |
| MITF | Microphthalmia-associated transcription factor |
| NADPH | Nicotinamide adenine dinucleotide phosphate (reduced form) |
| NF-κB | Nuclear factor kappa b |
| NLRP3 | Nod-like receptor family pyrin domain-containing 3 |
| Nrf2 | Nuclear factor erythroid 2–related factor 2 |
| ROS | Reactive oxygen species |
| RNS | Reactive nitrogen species |
| TGF-β | Transforming growth factor beta |
| TNF-α | Tumor necrosis factor alpha |
References
- Sies, H.; Berndt, C.; Jones, D.P. Oxidative stress. Annu. Rev. Biochem. 2017, 86, 715–748. [Google Scholar] [CrossRef] [Scilit]
- Jones, D.P. Redefining oxidative stress. Antioxid. Redox Signal. 2006, 8, 1865–1879. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Sies, H. Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: Oxidative eustress. Redox Biol. 2017, 11, 613–619. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Schieber, M.; Chandel, N.S. ROS function in redox signaling and oxidative stress. Curr. Biol. 2014, 24, R453–R462. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Holmström, K.M.; Finkel, T. Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat. Rev. Mol. Cell Biol. 2014, 15, 411–421. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Forman, H.J.; Maiorino, M.; Ursini, F. Signaling functions of reactive oxygen species. Biochemistry 2010, 49, 835–842. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Forman, H.J.; Zhang, H. Targeting oxidative stress in disease: Promise and limitations of antioxidant therapy. Nat. Rev. Drug Discov. 2021, 20, 689–709. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Winterbourn, C.C. Reconciling the chemistry and biology of reactive oxygen species. Nat. Chem. Biol. 2008, 4, 278–286. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Murphy, M.P.; Holmgren, A.; Larsson, N.G.; Halliwell, B.; Chang, C.J.; Kalyanaraman, B.; Rhee, S.G.; Thornalley, P.J.; Partridge, L.; Gems, D.; et al. Unraveling the biological roles of reactive oxygen species. Cell Metab. 2011, 13, 361–366. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Nathan, C.; Cunningham-Bussel, A. Beyond oxidative stress: An immunologist’s guide to reactive oxygen species. Nat. Rev. Immunol. 2013, 13, 349–361. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Calabrese, E.J.; Baldwin, L.A. Hormesis: The dose-response revolution. Annu. Rev. Pharmacol. Toxicol. 2003, 43, 175–197. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Calabrese, E.J. Hormetic mechanisms. Crit. Rev. Toxicol. 2013, 43, 580–606. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bocci, V. Ozone as Janus: This controversial gas can be either toxic or medically useful. Mediat. Inflamm. 2004, 13, 3–11. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bocci, V.; Borrelli, E.; Travagli, V.; Zanardi, I. The ozone paradox: Ozone is a strong oxidant as well as a medical drug. Med. Res. Rev. 2009, 29, 646–682. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Sagai, M.; Bocci, V. Mechanisms of action involved in ozone therapy: Is healing induced via a mild oxidative stress? Med. Gas Res. 2011, 1, 29. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bocci, V.A.; Zanardi, I.; Travagli, V. Ozone acting on human blood yields a hormetic dose-response relationship. J. Transl. Med. 2011, 9, 66. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bocci, V.; Zanardi, I.; Travagli, V. Oxygen/ozone as a medical gas mixture: A critical evaluation of the various methods clarifies positive and negative aspects. Med. Gas Res. 2011, 1, 6. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Elvis, A.M.; Ekta, J.S. Ozone therapy: A clinical review. J. Nat. Sci. Biol. Med. 2011, 2, 66–70. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Travagli, V.; Zanardi, I.; Bocci, V. A realistic evaluation of the action of ozone on whole human blood. Int. J. Biol. Macromol. 2006, 39, 317–320. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zanardi, I.; Borrelli, E.; Valacchi, G.; Travagli, V.; Bocci, V. Ozone: A multifaceted molecule with unexpected therapeutic activity. Curr. Med. Chem. 2016, 23, 304–314. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ayala, A.; Muñoz, M.F.; Argüelles, S. Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid. Med. Cell. Longev. 2014, 2014, 360438. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Higdon, A.; Diers, A.R.; Oh, J.Y.; Landar, A.; Darley-Usmar, V.M. Cell signalling by reactive lipid species: New concepts and molecular mechanisms. Biochem. J. 2012, 442, 453–464. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Uchida, K. 4-Hydroxy-2-nonenal: A product and mediator of oxidative stress. Prog. Lipid Res. 2003, 42, 318–343. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Yamamoto, M.; Kensler, T.W.; Motohashi, H. The KEAP1-NRF2 system: A thiol-based sensor-effector apparatus for maintaining redox homeostasis. Physiol. Rev. 2018, 98, 1169–1203. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Baird, L.; Yamamoto, M. The molecular mechanisms regulating the KEAP1-NRF2 pathway. Mol. Cell. Biol. 2020, 40, e00099-20. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Cuadrado, A.; Rojo, A.I.; Wells, G.; Hayes, J.D.; Cousin, S.P.; Rumsey, W.L.; Attucks, O.C.; Franklin, S.; Levonen, A.L.; Kensler, T.W.; et al. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat. Rev. Drug Discov. 2019, 18, 295–317. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Morgan, M.J.; Liu, Z.G. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res. 2011, 21, 103–115. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Liu, T.; Zhang, L.; Joo, D.; Sun, S.C. NF-κB signaling in inflammation. Signal Transduct. Target. Ther. 2017, 2, 17023. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Schroder, K.; Tschopp, J. The inflammasomes. Cell 2010, 140, 821–832. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- He, Y.; Hara, H.; Núñez, G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem. Sci. 2016, 41, 1012–1021. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zhou, R.; Yazdi, A.S.; Menu, P.; Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469, 221–225. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kelley, N.; Jeltema, D.; Duan, Y.; He, Y. The NLRP3 inflammasome: An overview of mechanisms of activation and regulation. Int. J. Mol. Sci. 2019, 20, 3328. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Swanson, K.V.; Deng, M.; Ting, J.P.Y. The NLRP3 inflammasome: Molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 2019, 19, 477–489. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Rinnerthaler, M.; Bischof, J.; Streubel, M.K.; Trost, A.; Richter, K. Oxidative stress in aging human skin. Biomolecules 2015, 5, 545–589. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Krutmann, J.; Bouloc, A.; Sore, G.; Bernard, B.A.; Passeron, T. The skin aging exposome. J. Dermatol. Sci. 2017, 85, 152–161. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kammeyer, A.; Luiten, R.M. Oxidation events and skin aging. Ageing Res. Rev. 2015, 21, 16–29. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Reilly, S.M.; Saltiel, A.R. Adapting to obesity with adipose tissue inflammation. Nat. Rev. Endocrinol. 2017, 13, 633–643. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Hotamisligil, G.S. Inflammation and metabolic disorders. Nature 2006, 444, 860–867. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Gregor, M.F.; Hotamisligil, G.S. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 2011, 29, 415–445. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Furukawa, S.; Fujita, T.; Shimabukuro, M.; Iwaki, M.; Yamada, Y.; Nakajima, Y.; Nakayama, O.; Makishima, M.; Matsuda, M.; Shimomura, I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Investig. 2004, 114, 1752–1761. [Google Scholar] [CrossRef] [PubMed]
- Quan, T.; Qin, Z.; Xia, W.; Shao, Y.; Voorhees, J.J.; Fisher, G.J. Matrix-degrading metalloproteinases in photoaging. J. Investig. Dermatol. Symp. Proc. 2009, 14, 20–24. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Fisher, G.J.; Kang, S.; Varani, J.; Bata-Csorgo, Z.; Wan, Y.; Datta, S.; Voorhees, J.J. Mechanisms of photoaging and chronological skin aging. Arch. Dermatol. 2002, 138, 1462–1470. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Pittayapruek, P.; Meephansan, J.; Prapapan, O.; Komine, M.; Ohtsuki, M. Role of matrix metalloproteinases in photoaging and photocarcinogenesis. Int. J. Mol. Sci. 2016, 17, 868. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Eming, S.A.; Martin, P.; Tomic-Canic, M. Wound repair and regeneration: Mechanisms, signaling, and translation. Sci. Transl. Med. 2014, 6, 265sr6. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Briganti, S.; Picardo, M. Antioxidant activity, lipid peroxidation and skin diseases: What’s new. J. Eur. Acad. Dermatol. Venereol. 2003, 17, 663–669. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Travagli, V.; Iorio, E.L. The biological and molecular action of ozone and its derivatives: State-of-the-art, enhanced scenarios, and quality insights. Int. J. Mol. Sci. 2023, 24, 8465. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Mudway, I.S.; Kelly, F.J. Ozone and the lung: A sensitive issue. Mol. Asp. Med. 2000, 21, 1–48. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kelly, F.J.; Fussell, J.C. Air pollution and airway disease. Clin. Exp. Allergy 2011, 41, 1059–1071. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Halliwell, B.; Gutteridge, J.M.C. Free Radicals in Biology and Medicine, 5th ed.; Oxford University Press: New York, NY, USA, 2015. [Google Scholar] [CrossRef] [Scilit]
- Alimohammadi, M.; Khoshnazar, S.M.; Khajehpour, H.; Izadi, M.; Einollahi, B.; Hushmandi, K. Effect of ozone therapy on oxidative stress indices in chronic inflammatory diseases: A systematic review and meta-analysis of randomized clinical trials. Adv. Redox Res. 2025, 17, 100143. [Google Scholar] [CrossRef] [Scilit]
- Viebahn-Haensler, R.; León Fernández, O.S. Ozone in medicine: The low-dose ozone concept and its basic biochemical mechanisms of action in chronic inflammatory diseases. Int. J. Mol. Sci. 2021, 22, 7890. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Pryor, W.A.; Squadrito, G.L.; Friedman, M. The cascade mechanism to explain ozone toxicity: The role of lipid ozonation products. Free Radic. Biol. Med. 1995, 19, 935–941. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Criegee, R. Mechanism of ozonolysis. Angew. Chem. Int. Ed. Engl. 1975, 14, 745–752. [Google Scholar] [CrossRef] [Scilit]
- Hassan, Z.; Lehmann, C.W.; Götte, M.; Alcarazo, M. Criegee Intermediates Beyond Ozonolysis: Synthetic and Mechanistic Insights. Angew. Chem. Int. Ed. 2021, 60, 15138–15152. [Google Scholar] [CrossRef] [Scilit]
- Esterbauer, H.; Schaur, R.J.; Zollner, H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 1991, 11, 81–128. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Schaur, R.J. Basic aspects of the biochemical reactivity of 4-hydroxynonenal. Mol. Asp. Med. 2003, 24, 149–159. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zarkovic, N. 4-Hydroxynonenal as a bioactive marker of pathophysiological processes. Mol. Asp. Med. 2003, 24, 281–291. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Marnett, L.J. Oxy radicals, lipid peroxidation and DNA damage. Toxicology 2002, 181–182, 219–222. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Girotti, A.W. Lipid hydroperoxide generation, turnover, and effector action in biological systems. J. Lipid Res. 1998, 39, 1529–1542. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Dinkova-Kostova, A.T.; Abramov, A.Y. The emerging role of Nrf2 in mitochondrial function. Free Radic. Biol. Med. 2015, 88, 179–188. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kobayashi, M.; Yamamoto, M. Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv. Enzym. Regul. 2006, 46, 113–140. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kansanen, E.; Kuosmanen, S.M.; Leinonen, H.; Levonen, A.L. The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. Redox Biol. 2013, 1, 45–49. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Tebay, L.E.; Robertson, H.; Durant, S.T.; Vitale, S.R.; Penning, T.M.; Dinkova-Kostova, A.T.; Hayes, J.D. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. Free Radic. Biol. Med. 2015, 88, 108–146. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ma, Q. Role of Nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol. 2013, 53, 401–426. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Hayes, J.D.; Dinkova-Kostova, A.T. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci. 2014, 39, 199–218. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Schäfer, M.; Werner, S. Nrf2—A regulator of keratinocyte redox signaling. Free Radic. Biol. Med. 2015, 88, 243–252. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Billingham, L.K.; Stoolman, J.S.; Vasan, K.; Rodriguez, A.E.; Poor, T.A.; Szibor, M.; Jacobs, H.T.; Reczek, C.R.; Rashidi, A.; Zhang, P.; et al. Mitochondrial electron transport chain is necessary for NLRP3 inflammasome activation. Nat. Immunol. 2022, 23, 692–704. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- O’Neill, L.A.; Pearce, E.J. Immunometabolism governs dendritic cell and macrophage function. J. Exp. Med. 2016, 213, 15–23. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Mills, E.L.; Kelly, B.; Logan, A.; Costa, A.S.H.; Varma, M.; Bryant, C.E.; Tourlomousis, P.; Däbritz, J.H.M.; Gottlieb, E.; Latorre, I.; et al. Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell 2016, 167, 457–470.e13. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Galván-Peña, S.; O’Neill, L.A.J. Metabolic reprogramming in macrophage polarization. Front. Immunol. 2014, 5, 420. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kelly, B.; O’Neill, L.A.J. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res. 2015, 25, 771–784. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Van den Bossche, J.; O’Neill, L.A.J.; Menon, D. Macrophage immunometabolism: Where are we (going)? Trends Immunol. 2017, 38, 395–406. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Stincone, A.; Prigione, A.; Cramer, T.; Wamelink, M.M.; Campbell, K.; Cheung, E.; Olin-Sandoval, V.; Grüning, N.M.; Krüger, A.; Tauqeer Alam, M.; et al. The return of metabolism: Biochemistry and physiology of the pentose phosphate pathway. Biol. Rev. 2015, 90, 927–963. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Newman, J.C.; He, W.; Verdin, E. Mitochondrial protein acylation and intermediary metabolism: Regulation by sirtuins and implications for metabolic disease. J. Biol. Chem. 2012, 287, 42436–42443. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Murphy, M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009, 417, 1–13. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kaludercic, N.; Deshwal, S.; Di Lisa, F. Reactive oxygen species and redox compartmentalization. Front. Physiol. 2014, 5, 285. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lennicke, C.; Cochemé, H.M. Redox metabolism: ROS as specific molecular regulators of cell signaling and function. Mol. Cell 2021, 81, 3691–3707. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Sies, H.; Jones, D.P. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat. Rev. Mol. Cell Biol. 2020, 21, 363–383. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Go, Y.M.; Jones, D.P. Redox compartmentalization in eukaryotic cells. Biochim. Biophys. Acta 2008, 1780, 1273–1290. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Tonelli, C.; Chio, I.I.C.; Tuveson, D.A. Transcriptional regulation by Nrf2. Antioxid. Redox Signal. 2018, 29, 1727–1745. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Karin, M. NF-κB as a critical link between inflammation and cancer. Cold Spring Harb. Perspect. Biol. 2009, 1, a000141. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lawrence, T. The nuclear factor NF-κB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 2009, 1, a001651. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Komanapalli, I.R.; Lau, B.H.S. Ozone-induced damage of Escherichia coli K-12. Appl. Microbiol. Biotechnol. 1996, 46, 610–614. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bauernfeind, F.G.; Horvath, G.; Stutz, A.; Alnemri, E.S.; MacDonald, K.; Speert, D.; Fernandes-Alnemri, T.; Wu, J.; Monks, B.G.; Fitzgerald, K.A.; et al. Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 2009, 183, 787–791. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- O’Neill, L.A.J.; Kishton, R.J.; Rathmell, J. A guide to immunometabolism for immunologists. Nat. Rev. Immunol. 2016, 16, 553–565. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wen, Q.; Liu, D.; Wang, X.; Zhang, Y.; Fang, S.; Qiu, X.; Chen, Q. A systematic review of ozone therapy for treating chronically refractory wounds and ulcers. Int. Wound J. 2022, 19, 853–870. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lefkimmiatis, K.; Zaccolo, M. cAMP signaling in subcellular compartments. Pharmacol. Ther. 2014, 143, 295–304. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Greenberg, A.S.; Coleman, R.A.; Kraemer, F.B.; McManaman, J.L.; Obin, M.S.; Puri, V.; Yan, Q.W.; Miyoshi, H.; Mashek, D.G. The role of lipid droplets in metabolic disease in rodents and humans. J. Clin. Investig. 2011, 121, 2102–2110. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Slominski, A.; Tobin, D.J.; Shibahara, S.; Wortsman, J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol. Rev. 2004, 84, 1155–1228. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Denat, L.; Kadekaro, A.L.; Marrot, L.; Leachman, S.A.; Abdel-Malek, Z.A. Melanocytes as instigators and victims of oxidative stress. J. Investig. Dermatol. 2014, 134, 1512–1518. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- D’Mello, S.A.; Finlay, G.J.; Baguley, B.C.; Askarian-Amiri, M.E. Signaling pathways in melanogenesis. Int. J. Mol. Sci. 2016, 17, 1144. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Hearing, V.J. Determination of melanin synthetic pathways. J. Investig. Dermatol. 2011, 131, E8–E11. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Smith, N.L.; Wilson, A.L.; Gandhi, J.; Vatsia, S.; Khan, S.A. Ozone therapy: An overview of pharmacodynamics, current research, and clinical utility. Med. Gas Res. 2017, 7, 212–219. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Liu, Q.; Liu, J.; Cao, G.; Liu, Y.; Huang, Y.; Jiang, X. Ozone therapy for knee osteoarthritis: A literature visualization analysis of research hotspots and prospects. Med. Gas Res. 2025, 15, 356–365. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Mattson, M.P. Hormesis defined. Ageing Res. Rev. 2008, 7, 1–7. [Google Scholar] [CrossRef] [Scilit] [PubMed]

| Pathway/Regulatory Axis | Principal Molecular Trigger | Biological Consequence | Predominant Functional Outcome | Representative References |
|---|---|---|---|---|
| Nrf2–Keap1 pathway | Electrophilic cysteine modification and peroxide-mediated signaling | Antioxidant transcriptional activation and metabolic reinforcement | Adaptive redox reprogramming | [24,25,26,60,61,62,63,64,65,79,80] |
| NF-κB signaling | Redox-sensitive inflammatory activation | Transcription of inflammatory cytokines and adhesion molecules | Inflammatory amplification | [27,28,81,82] |
| NLRP3 inflammasome | Mitochondrial ROS generation; ionic fluxes; redox stress | Caspase-1 activation and IL-1β maturation | Innate inflammatory activation | [29,30,31,32,33,67,84] |
| Immunometabolic pathways | Redox-dependent metabolic rewiring | Glycolytic and oxidative metabolic reprogramming | Immune adaptation and inflammatory modulation | [68,69,70,71,72,73,74,85] |
| Redox compartmentalization | Localized ROS and electrophile signaling | Spatially restricted adaptive signaling | Context-dependent tissue adaptation | [76,77,78,79] |
| Inflammatory redox integration | Crosstalk between antioxidant and inflammatory signaling pathways | Coordination of antioxidant buffering capacity and inflammatory priming | Systems-level inflammatory recalibration | [24,25,26,27,28,63,64,65,81,82] |
| Biological Compartment | Redox Regulatory Node | Molecular Mechanism | Systems-Level Consequence | Predominant Evidence Context | Representative References |
|---|---|---|---|---|---|
| Dermal fibroblasts | Keap1–Nrf2 signaling axis | Electrophile-mediated cysteine modification; induction of glutathione biosynthesis and peroxide-detoxifying enzymes | Reinforcement of intracellular redox buffering; modulation of matrix synthesis–degradation balance | In vitro; selected in vivo models | [24,25,26,63,64,65,66] |
| Dermal fibroblasts | Redox modulation of cytokine networks | Attenuation of NF-κB-dependent transcription; limitation of oxidant-driven amplification loops | Shift toward matrix remodeling profiles compatible with reparative responses | In vitro; selected in vivo models | [27,28,34,35,36,37,38,39,40,41,42,43,44,45,66] |
| Adipocytes | cAMP-dependent metabolic signaling | Redox-sensitive modulation of phosphodiesterase and kinase activity; indirect regulation of hormone-sensitive lipase | Context-dependent modulation of triglyceride mobilization and metabolic adaptation | In vitro; limited in vivo evidence | [68,69,70,71,72,73,74,87,88] |
| Adipose tissue | Nrf2-driven metabolic adaptation | Induction of antioxidant and NADPH-regenerating pathways | Redox-mediated attenuation of oxidative stress-associated adipogenic signaling; potential immunometabolic rebalancing | Predominantly in vitro | [24,25,26,37,38,39,40,65,68,69,70,71,72,85] |
| Melanocytes | Redox control of melanogenic enzymes | Modulation of intracellular oxidative tone affecting tyrosinase activity and thiol availability | Stabilization of melanogenic flux under controlled redox conditions | In vitro | [89,90,91,92] |
| Melanocytes | Redox-sensitive transcriptional regulation | Indirect modulation of microphthalmia-associated transcription factor activity via oxidative and inflammatory signaling | Redox-mediated adjustment of pigment homeostasis | In vitro | [26,66,89,90,91,92] |
| Innate immune cells | NLRP3 inflammasome regulation | Modulation of redox-associated activation signals; attenuation of caspase-1 activation | Potential attenuation of pro-inflammatory cytokine maturation | In vitro and in vivo models | [29,30,31,32,33,67,84] |
| Innate immune cells | Nrf2 pathway–NF-κB signaling network interaction | Reinforcement of antioxidant transcriptional programs; modulation of inflammatory priming | Recalibration of inflammatory signaling networks | In vitro and in vivo models | [24,25,26,27,28,63,64,65,81,82] |
| Epidermal and dermal cells | Redox-dependent proteostasis | Maintenance of thiol homeostasis; support of lysosomal and proteolytic function | Preservation of cellular turnover and structural integrity | In vitro; selected in vivo models | [34,35,36,65,66] |
| Cutaneous–subcutaneous unit | Integrated redox network response | Coordinated transcriptional, metabolic, and inflammatory adaptation following localized redox perturbation | Systems-level redox re-equilibration within a constrained adaptive range | Mechanistic integration of experimental evidence | [11,12,15,16,24,25,26,27,28,68,69,70,71,72,76,77,78,79,80] |
| Ozone-Induced Condition | Predominant Redox Events | Adaptive Responses | Potential Pathological Consequences | Representative References |
|---|---|---|---|---|
| Low-dose/controlled exposure | Transient electrophile formation; moderate peroxide generation; localized thiol oxidation | Nrf2 activation; antioxidant reinforcement; metabolic adaptation; reinforcement of redox buffering capacity | Minimal or absent structural injury | [11,12,15,16,24,25,26,63,64,65,95] |
| Intermediate exposure | Increased lipid oxidation; partial saturation of antioxidant buffering systems | Context-dependent adaptive signaling with variable tissue responsiveness | Moderate oxidative stress and inflammatory amplification | [21,22,23,55,56,57,60,61,62,63,64,65,76,77,78,79,80] |
| Excessive exposure | ROS amplification; thiol depletion; mitochondrial dysfunction; propagation of lipid oxidation | Failure of adaptive redox compensation | Protein oxidation; inflammasome activation; tissue injury; inflammatory amplification | [21,22,23,30,31,32,33,55,56,57,58,67,68,69,70,71,72,73,74,75] |
| Biological Process | Representative Biomarkers | Common Biological Matrix | Potential Translational Relevance | Representative References |
|---|---|---|---|---|
| Oxidative damage | Protein carbonyls; 4-HNE; lipid hydroperoxides | Tissue; plasma; wound exudate | Assessment of oxidative injury | [21,22,23,55,56,57,58,59] |
| Adaptive redox signaling | GSH/GSSG ratio; HO-1; NQO1; expression of Nrf2 target genes | Tissue; blood | Evaluation of adaptive redox responses | [24,25,26,60,61,62,63,64,65] |
| Inflammatory activation | IL-1β; TNF-α; IL-6; NLRP3-related markers | Blood; wound exudate; tissue | Assessment of inflammatory modulation | [27,28,29,30,31,32,33,67,81,82,84] |
| Integrated biomarker assessment | Combined evaluation of oxidative damage, adaptive redox signaling, and inflammatory biomarkers | Blood and/or tissue | Integrated evaluation of biological responses | [7,46,50,51] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Perra, F.; Cannea, F.B.; Padiglia, A. Ozone Therapy as a Controlled Modulator of Redox Signaling and Adaptive Stress Responses: Molecular Mechanisms, Hormetic Effects, and Biomedical Implications. Oxygen 2026, 6, 18. https://doi.org/10.3390/oxygen6030018
Perra F, Cannea FB, Padiglia A. Ozone Therapy as a Controlled Modulator of Redox Signaling and Adaptive Stress Responses: Molecular Mechanisms, Hormetic Effects, and Biomedical Implications. Oxygen. 2026; 6(3):18. https://doi.org/10.3390/oxygen6030018
Chicago/Turabian StylePerra, Francesca, Faustina Barbara Cannea, and Alessandra Padiglia. 2026. "Ozone Therapy as a Controlled Modulator of Redox Signaling and Adaptive Stress Responses: Molecular Mechanisms, Hormetic Effects, and Biomedical Implications" Oxygen 6, no. 3: 18. https://doi.org/10.3390/oxygen6030018
APA StylePerra, F., Cannea, F. B., & Padiglia, A. (2026). Ozone Therapy as a Controlled Modulator of Redox Signaling and Adaptive Stress Responses: Molecular Mechanisms, Hormetic Effects, and Biomedical Implications. Oxygen, 6(3), 18. https://doi.org/10.3390/oxygen6030018

